Skip to main content
Toggle navigation
Search
Home
Hematologic
Home
Hematologic
Hematologic
Type here to filter the list
(220) Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database
(221) Transfusion-related Cost and Time Burden Offsets in Patients with Myelofibrosis Treated with Pacritinib Compared to Best Available Therapy Based on PERSIST-2 Trial
(222) Real-world iptacopan use among United States patients with paroxysmal nocturnal hemoglobinuria
(223) Fitusiran Prophylaxis Reduces Episodic Treatment-Associated Costs of Managing Breakthrough Bleeds in Hemophilia
(224) Real-world experience with efanesoctocog alfa in patients with moderate and severe hemophilia A: Final analysis of the Adelphi hemophilia wave III disease specific programmeTM
(225) Treatment Patterns, Healthcare Resource Utilization (HCRU), and Costs in Adolescent and Young Adult (AYA) Patients (Pts) With Acute Lymphoblastic Leukemia (ALL)
(226) Healthcare Resource Utilization and Costs Before and After Diagnosis of Idiopathic Multicentric Castleman Disease in the United States
(227) Impact of acute pain and fatigue on health care resource utilization and costs in sickle cell disease in the United States
(228) Resource utilization and economic burden amongst a cohort of patients with hemophilia without inhibitors in the United States
(229) Mitapivat treatment usage, satisfaction and adherence among adults with pyruvate kinase deficiency in the United States
(230) The economic burden of immune thrombocytopenia in the United States: insights from a systematic literature review and key evidence gaps
(231) Real-world impact on work and school among adults with pyruvate kinase deficiency in the United States
(232) Impact of emicizumab on real-world healthcare resource utilization in the US
